- Juniper Pharmaceuticals (NASDAQ:JNP) announces that Merck KGaA (OTCPK:MKGAY) has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for OneCrinone 90 mg (progesterone) for the indication of luteal phase supplementation in assisted reproductive treatment.
- This approval further expands the global Crinone progesterone gel franchise into the world's' third largest pharmaceutical market, giving women and couples struggling with infertility in Japan a new, patient-friendly therapeutic option for luteal phase support
- The market launch should commence later this year.
- Merck KGaA has global rights (ex-U.S.) to Crinone and OneCrinone. Allergan (AGN) owns the U.S. rights.